Astellas Beats $115M Milestone Claim In Del. Chancery Ruling
A Delaware Court of Chancery judge has ruled that Astellas Pharma Inc. is not obligated to pay up to $115 million in disputed drug development milestone payments tied to its acquisition...To view the full article, register now.
Already a subscriber? Click here to view full article